MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ
1.610
+0.020
+1.26%
Opening 12:31 12/05 EST
OPEN
1.610
PREV CLOSE
1.590
HIGH
1.680
LOW
1.610
VOLUME
336.42K
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
1.350
MARKET CAP
120.81M
P/E (TTM)
-16.1972
1D
5D
1M
3M
1Y
5Y
1D
Eledon Pharmaceuticals CEO to Join Fireside Chat at Piper Sandler Healthcare Conference
Reuters · 4d ago
Weekly Report: what happened at ELDN last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at ELDN last week (1117-1121)?
Weekly Report · 11/24 10:32
Eledon Pharmaceuticals Reports Q3 2025 Financial Results
TipRanks · 11/20 03:57
Eledon Pharmaceuticals reports preliminary tegoprubart trial results
TipRanks · 11/18 21:15
Eledon Pharmaceuticals Data From First Six Participants Of Investigator-Initiated Study Of Anti-CD40 Ligand Demonstrates Marked Improvements In Glycemic Control
Benzinga · 11/18 21:08
Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes
Reuters · 11/18 21:05
ELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTS
Reuters · 11/18 21:05
More
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Webull offers Eledon Pharmaceuticals Inc stock information, including NASDAQ: ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.